Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence

Tyrosine kinase inhibitors (TKIs) against human epidermal growth factor receptor (EGFR/HER) family have been introduced into the clinic to treat cancers, particularly non-small-cell lung cancer (NSCLC). There have been three generations of the EGFR/HER-TKIs. First-generation EGFR/HER-TKIs, binding c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaochun, Goldstein, David, Crowe, Philip J, Yang, Jia-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021053/
https://www.ncbi.nlm.nih.gov/pubmed/27660463
http://dx.doi.org/10.2147/OTT.S94745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021053/
https://www.ncbi.nlm.nih.gov/pubmed/27660463
http://dx.doi.org/10.2147/OTT.S94745

Ejemplares similares